We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Neurogene

News List

Neurogene closes $115m series B financing pharmaceutical-business-review
December 21, 2020
Neurogene, a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115m Series B financing.
Neurogene announces EMA grants orphan drug designation for aspartylglucosaminuria gene therapy pharmaceutical-business-review
December 09, 2020
Neurogene announces that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to its adeno-associated virus vector (AAV) with engineered transgene encoding the human AGA gene for patients diagnosed with aspartylglucosaminuria.
Neurogene raises funds to support gene therapy development pharmaceutical-technology
February 15, 2019
Neurogene has secured funding during a Series A financing round to advance the development of its gene therapy candidates intended for the treatment of various neurological diseases....